製品番号: HY-119272

EF24

2 Cited Publications

カスタマーレビュー

Based on 2 publication(s) in Google Scholar

EF24, a curcumin analogue, is an NF-kB inhibitor with great anti-tumor efficacy and oral bioavailability via deactivation of the MAPK/ERK signaling pathway in oral squamous cell carcinoma (OSCC). EF24 is active against melanoma and breast cancer cell lines with GI₅₀ values of 0.7 μM and 0.8 μM, respectively. EF24 induces cell cycle arrest and apoptosis in MDA-MB-231 human breast cancer cells and DU-145 human prostate cancer cells. EF24 increases the levels of activated caspase 3 and 9, and decreases the phosphorylated forms of MEK1 and ERK.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

純度: 99.34%
CAS 番号: 342808-40-6
分子式: C₁₉H₁₅F₂NO
分子量:311.33

保管条件:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

EF24 構造式

CAS 番号: 342808-40-6

容量

価格（税別）

在庫状況

数量

Amount: USD 0.00

* アイテムを追加する前、数量をご選択ください

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

生物活性
- 製品説明
- Cellular Effect
- 体外実験
- 体内実験
化学情報
Publications (2)
溶剤 & 溶解度
- 体外
- 体内
純度とドキュメンテーション
参考文献
Help & FAQs
関連分類
Bioz

生物活性

製品説明

ERK アイソフォーム固有の製品をすべて表示 :

Caspase アイソフォーム固有の製品をすべて表示 :

NF-κB アイソフォーム固有の製品をすべて表示 :

p38 MAPK アイソフォーム固有の製品をすべて表示 :

Cellular Effect

Cell Line	Type	Value	Description	References
518A2	IC₅₀	1.8 μM Compound: 2; EF24	Cytotoxicity against human 518A2 cells after 72 hrs by MTT assay Cytotoxicity against human 518A2 cells after 72 hrs by MTT assay	[PMID: 28774574]
A2780	IC₅₀	0.5 μM Compound: EF24	Cell viability of human cisplatin-sensitive human A2780 cells after 24 hrs by MTT assay Cell viability of human cisplatin-sensitive human A2780 cells after 24 hrs by MTT assay	[PMID: 17684018]
A2780	IC₅₀	0.65 μM Compound: EF24	Cell viability of cisplatin-resistant human A2780 cells after 24 hrs by MTT assay Cell viability of cisplatin-resistant human A2780 cells after 24 hrs by MTT assay	[PMID: 17684018]
A549	IC₅₀	1.3 μM Compound: 1, EF24	Inhibition of NF-kappaB nuclear translocation in human A549 cells Inhibition of NF-kappaB nuclear translocation in human A549 cells	[PMID: 19854644]
A549	IC₅₀	2.4 μM Compound: EF24	Cytotoxicity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 29655083]
A549	IC₅₀	2.8 μM Compound: A1; EF24	Antiproliferative activity against human A549 cells after 72 hrs by MTT assay Antiproliferative activity against human A549 cells after 72 hrs by MTT assay	[PMID: 29351887]
A549	IC₅₀	7.1 μM Compound: EF24	Cytotoxicity against human A549 cells measured after 72 hrs by MTT assay Cytotoxicity against human A549 cells measured after 72 hrs by MTT assay	[PMID: 27886548]
CHO	IC₅₀	4.6 μM Compound: EF24	Cell viability of CHO cells after 24 hrs by MTT assay Cell viability of CHO cells after 24 hrs by MTT assay	[PMID: 17684018]
DLD-1	IC₅₀	1.3 μM Compound: 2; EF24	Cytotoxicity against human DLD1 cells after 72 hrs by MTT assay Cytotoxicity against human DLD1 cells after 72 hrs by MTT assay	[PMID: 28774574]
HCT-116	IC₅₀	1.5 μM Compound: 2; EF24	Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay	[PMID: 28774574]
HEK293	CC₅₀	3.58 μM Compound: 33	Cytotoxicity against human HEK293 cells assessed as reduction in cell viability at 20 uM measured after 48 hrs by resazurin reagent based multilabel reader analysis Cytotoxicity against human HEK293 cells assessed as reduction in cell viability at 20 uM measured after 48 hrs by resazurin reagent based multilabel reader analysis	[PMID: 36608774]
HeLa 229	IC₅₀	1.9 μM Compound: A1; EF24	Antiproliferative activity against human HeLa 229 cells after 72 hrs by MTT assay Antiproliferative activity against human HeLa 229 cells after 72 hrs by MTT assay	[PMID: 29351887]
HepG2	IC₅₀	3.33 μM Compound: EF24	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 30771605]
HT-29	IC₅₀	1.6 μM Compound: 2; EF24	Cytotoxicity against human HT-29 cells after 72 hrs by MTT assay Cytotoxicity against human HT-29 cells after 72 hrs by MTT assay	[PMID: 28774574]
L02	IC₅₀	10.2 μM Compound: EF24	Cytotoxicity against human LO2 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Cytotoxicity against human LO2 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 30771605]
L02	IC₅₀	5.1 μM Compound: EF24	Cytotoxicity against human HL7702 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human HL7702 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 29655083]
L02	IC₅₀	5.8 μM Compound: EF24	Antiproliferative activity against human HL7702 cells by MTT assay Antiproliferative activity against human HL7702 cells by MTT assay	[PMID: 31336310]
Lewis lung carcinoma cell line	IC₅₀	8.4 μM Compound: EF24	Cytotoxicity against mouse LLC cells measured after 72 hrs by MTT assay Cytotoxicity against mouse LLC cells measured after 72 hrs by MTT assay	[PMID: 27886548]
MDA-MB-231	IC₅₀	5.6 μM Compound: A1	Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell proliferation by CCK-8 assay Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell proliferation by CCK-8 assay	[PMID: 38746900]
MDA-MB-435	IC₅₀	1.5 μM Compound: 1, EF24	Cytotoxicity against human MDA-MB-435 cells Cytotoxicity against human MDA-MB-435 cells	[PMID: 19854644]
MGC-803	IC₅₀	2 μM Compound: A1; EF24	Antiproliferative activity against human MGC803 cells after 72 hrs by MTT assay Antiproliferative activity against human MGC803 cells after 72 hrs by MTT assay	[PMID: 29351887]
NB-4	IC₅₀	0.29 μM Compound: 42	Cytotoxicity against human NB4 cells assessed as reduction in cell viability after 72 hrs by MTS assay Cytotoxicity against human NB4 cells assessed as reduction in cell viability after 72 hrs by MTS assay	[PMID: 24960549]
NCI-H1650	IC₅₀	1.7 μM Compound: EF24	Cytotoxicity against human NCI-H1650 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human NCI-H1650 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 29655083]
NCI-H1650	IC₅₀	14.6 μM Compound: EF24	Cytotoxicity against human NCI-H1650 cells measured after 72 hrs by MTT assay Cytotoxicity against human NCI-H1650 cells measured after 72 hrs by MTT assay	[PMID: 27886548]
NCI-H1975	IC₅₀	1.3 μM Compound: EF24	Cytotoxicity against human NCI-H1975 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human NCI-H1975 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 29655083]
NCI-H441	IC₅₀	44 μM Compound: 1	Antiproliferative activity against human H441 cells assessed as decrease of hexosaminidase activity after 24 hrs Antiproliferative activity against human H441 cells assessed as decrease of hexosaminidase activity after 24 hrs	[PMID: 20638855]
NCI-H460	IC₅₀	1.2 μM Compound: EF24	Cytotoxicity against human H460 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human H460 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 29655083]
NCI-H460	IC₅₀	6 μM Compound: EF24	Antiproliferative activity against human H460 cells by MTT assay Antiproliferative activity against human H460 cells by MTT assay	[PMID: 31336310]
PANC-1	IC₅₀	1.5 μM Compound: 2; EF24	Cytotoxicity against human PANC1 cells after 72 hrs by MTT assay Cytotoxicity against human PANC1 cells after 72 hrs by MTT assay	[PMID: 28774574]
QGY-7703	IC₅₀	4.97 μM Compound: EF24	Cytotoxicity against human QGY7703 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Cytotoxicity against human QGY7703 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 30771605]
SGC-7901	IC₅₀	1 μM Compound: A1; EF24	Antiproliferative activity against human SGC7901 cells after 72 hrs by MTT assay Antiproliferative activity against human SGC7901 cells after 72 hrs by MTT assay	[PMID: 29351887]
SGC-7901	IC₅₀	6.5 μM Compound: EF24	Antiproliferative activity against human SGC7901 cells by MTT assay Antiproliferative activity against human SGC7901 cells by MTT assay	[PMID: 31336310]
SMMC-7721	IC₅₀	8.8 μM Compound: EF24	Cytotoxicity against human SMMC7721 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Cytotoxicity against human SMMC7721 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 30771605]
U-251	IC₅₀	4.5 μM Compound: EF24	Antiproliferative activity against human U251 cells by MTT assay Antiproliferative activity against human U251 cells by MTT assay	[PMID: 31336310]
U-87MG ATCC	IC₅₀	1.4 μM Compound: 2; EF24	Cytotoxicity against human U87 cells after 72 hrs by MTT assay Cytotoxicity against human U87 cells after 72 hrs by MTT assay	[PMID: 28774574]

体外実験

EF24 (0-10 μM) exhibits cytotoxicity against human breast cancer cells in a dose-dependent increase^[2].
EF24 (0.1-100 μM, 6-72 h) effectively inhibits the active synthesis of DNA in both DU-145 prostate cancer cells and MDA-MB-231 breast cancer cells^[3].
EF24 (20 μM, 24-72 h) induces cell cycle arrest and apoptosis by means of a redox-dependent mechanism and produces a time-dependent increase in intracellular ROS in MDA-MB-231 human breast cancer cells and DU-145 human prostate cancer cells^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay^[3]

Cell Line:

DU-145 prostate cancer cells and MDA-MB-231 breast cancer cells
Concentration:

0.1-100 μM
Incubation Time:

6-72 h
Result:

Demonstrates approximately 40% inhibition at 1 μM (10^-6 M) after a 72-h treatment in the breast cancer cells.

Cell Cycle Analysis^[3]

Cell Line:

DU-145 prostate cancer cells and MDA-MB-231 breast cancer cells
Concentration:

20 μM
Incubation Time:

24-72 h
Result:

Caused a G2/M arrest in both cell lines.

体内実験

EF24 (0.4 mg/kg, i.p., a single dose for 6 h) markedly ameliorates the post-hemorrhage morphologic changes and inflammatory cell infiltration, inhibits hemorrhage-induced NF-kB phosphorylation in rat model of hemorrhage^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Rat model of hemorrhage^[4]
Dosage:

0.4 mg/kg
Administration:

i.p., a single dose for 6 h
Result:

Prevented the hemorrhage-induced increase in myeloperoxidase activity and phospho-NF-kB p65 in hemorrhaged lung tissue.

化学情報

CAS 番号 342808-40-6
性状 Solid
分子量 311.33
分子式 C₁₉H₁₅F₂NO
Color White to yellow
SMILES

O=C1/C(CNC/C1=C\C2=C(C=CC=C2)F)=C/C3=C(C=CC=C3)F
輸送条件

Room temperature in continental US; may vary elsewhere.

保管条件

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (2)

All

Sort by:

Journal Impact Factor

Phytomedicine

Curcumin analogue EF24 prevents alveolar epithelial cell senescence to ameliorate idiopathic pulmonary fibrosis via activation of PTEN. [Abstract]

2024 Jul 27:133:155882. PMID: 39096545
bioRxiv

2025 May 23.

溶剤 & 溶解度

体外:

DMSO : 50 mg/mL (160.60 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

3.2120 mL

16.0601 mL

32.1203 mL

5 mM

0.6424 mL

3.2120 mL

6.4241 mL

10 mM

0.3212 mL

1.6060 mL

3.2120 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

モル濃度計算機

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

濃度濃度

体積体積

分子量分子量

希釈計算機

濃度 _(開始) × 体積 _(開始) = 濃度 _(終了) × 体積 _(終了)

濃度 _(開始) 濃度 _(開始)

体積 _(開始) 体積 _(開始)

濃度 _(終了) 濃度 _(終了)

体積 _(終了) 体積 _(終了)

体内:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: 2.5 mg/mL (8.03 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: 2.5 mg/mL (8.03 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

純度とドキュメンテーション

バッチを選択:

純度: 99.98%

Assay: 99.98%

ee.: 99.98%

データシート (278 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
元素分析報告書 (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
取扱説明書 (2659 KB)

参考文献

[1]. Lelli D, et al. Curcumin and treatment of melanoma: The potential role of microRNAs. Biomed Pharmacother. 2017 Apr;88:832-834. [Content Brief]

[2]. Mosley CA, et al. Highly active anticancer curcumin analogues. Adv Exp Med Biol. 2007;595:77-103. [Content Brief]

[3]. Adams BK, et al. EF24, a novel synthetic curcumin analog, induces apoptosis in cancer cells via a redox-dependent mechanism. Anticancer Drugs. 2005 Mar;16(3):263-75. [Content Brief]

[4]. Yadav VR, et al. Pharmacologic suppression of inflammation by a diphenyldifluoroketone, EF24, in a rat model of fixed-volume hemorrhage improves survival. J Pharmacol Exp Ther. 2013 Nov;347(2):346-56. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	3.2120 mL	16.0601 mL	32.1203 mL	80.3006 mL
	5 mM	0.6424 mL	3.2120 mL	6.4241 mL	16.0601 mL
	10 mM	0.3212 mL	1.6060 mL	3.2120 mL	8.0301 mL
	15 mM	0.2141 mL	1.0707 mL	2.1414 mL	5.3534 mL
	20 mM	0.1606 mL	0.8030 mL	1.6060 mL	4.0150 mL
	25 mM	0.1285 mL	0.6424 mL	1.2848 mL	3.2120 mL
	30 mM	0.1071 mL	0.5353 mL	1.0707 mL	2.6767 mL
	40 mM	0.0803 mL	0.4015 mL	0.8030 mL	2.0075 mL
	50 mM	0.0642 mL	0.3212 mL	0.6424 mL	1.6060 mL
	60 mM	0.0535 mL	0.2677 mL	0.5353 mL	1.3383 mL
	80 mM	0.0402 mL	0.2008 mL	0.4015 mL	1.0038 mL
	100 mM	0.0321 mL	0.1606 mL	0.3212 mL	0.8030 mL

Keywords

EF24

2 Cited Publications

100 mg お問い合わせ

Subscribe to the

MedChemExpress

Newsletter

製品名:
製品番号:
数量:
日本の代理先をお選びください:

製品名:
CAS 番号:
生物種:
純度:
数量:

EF24

Apoptosis Compound Library

Immunology/Inflammation Compound Library

Kinase Inhibitor Library

MAPK Compound Library

Metabolism/Protease Compound Library

NF-κB Signaling Compound Library

Stem Cell Signaling Compound Library

Anti-Cancer Compound Library

Anti-Aging Compound Library

Antioxidant Compound Library

Differentiation Inducing Compound Library

Reprogramming Compound Library

Oxygen Sensing Compound Library

Pyroptosis Compound Library

Orally Active Compound Library

Glutamine Metabolism Compound Library

Anti-Breast Cancer Compound Library

Anti-Lung Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Neurodegenerative Disease-related Compound Library

Anti-Obesity Compound Library

Angiogenesis-Related Compound Library

Transcription Factor-Targeted Library

Anti-Liver Cancer Compound Library

Anti-Colorectal Cancer Compound Library

Antidepressant Compound Library

Anti-Prostate Cancer Compound Library

Anti-Pulmonary Fibrosis Compound Library

Cancer Stem Cells Compound Library

Heterocyclic Compound Library

Pain-Related Compound Library

Cysteine Targeted Covalent Library

Cell Death Library

Serine/Threonine Kinase Inhibitor Library

Anti-Hematopathy Compound Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

Radioprotector Library

Bioactive Compound Library Max

Bioactive Compound Library

Anti-Gastric Cancer Compound Library

Anti-Fibrosis Compound Library

Protein Kinase Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

Anti-Rheumatic Arthritis Compound Library

Posttranslational Modification Library

Lactylation Compound Library

MedChemExpress（MCE）の使用を引用している文献 EF24

ERK アイソフォーム固有の製品をすべて表示

Caspase アイソフォーム固有の製品をすべて表示

NF-κB アイソフォーム固有の製品をすべて表示

p38 MAPK アイソフォーム固有の製品をすべて表示

生物活性

化学情報

Publications (2)

溶剤 & 溶解度

純度とドキュメンテーション

参考文献

Help & FAQs

Complete Stock Solution Preparation Table

EF24 関連分類

HY-119272 関連分類